AbCellera Biologics Inc (NASDAQ: ABCL) on Monday, soared 16.67% from the previous trading day, before settling in for the closing price of $2.70. Within the past 52 weeks, ABCL’s price has moved between $2.34 and $6.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 387.52% over the past five years. The company achieved an average annual earnings per share of -12.89%. With a float of $207.08 million, this company’s outstanding shares have now reached $290.82 million.
Let’s look at the performance matrix of the company that is accounted for 586 employees. In terms of profitability, gross margin is -179.73%, operating margin of -934.58%, and the pretax margin is -613.32%.
AbCellera Biologics Inc (ABCL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of AbCellera Biologics Inc is 29.89%, while institutional ownership is 33.16%.
AbCellera Biologics Inc (ABCL) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.17 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.13) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.89% per share during the next fiscal year.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
AbCellera Biologics Inc (ABCL) is currently performing well based on its current performance indicators. A quick ratio of 9.34 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.60, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
AbCellera Biologics Inc (NASDAQ: ABCL) saw its 5-day average volume 3.54 million, a positive change from its year-to-date volume of 1.67 million. As of the previous 9 days, the stock’s Stochastic %D was 66.64%. Additionally, its Average True Range was 0.18.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 64.43%, which indicates a significant decrease from 95.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.94% in the past 14 days, which was higher than the 61.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.65, while its 200-day Moving Average is $3.54. Nevertheless, the first resistance level for the watch stands at $3.31 in the near term. At $3.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.77. If the price goes on to break the first support level at $2.85, it is likely to go to the next support level at $2.56. The third support level lies at $2.39 if the price breaches the second support level.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
Market capitalization of the company is 923.56 million based on 295,366K outstanding shares. Right now, sales total 38,030 K and income totals -146,400 K. The company made 7,320 K in profit during its latest quarter, and -36,930 K in sales during its previous quarter.
